At the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, SiBionics unveiled its integrated continuous glucose monitoring (CGM) and continuous ketone monitoring (CKM) solutions, receiving significant recognition from global diabetes researchers. The symposium, titled “CGM + CKM for Better Diabetes Management,” facilitated discussions among leading experts, highlighting SiBionics’ innovative approach and its potential impact on diabetes care.
The conference featured prominent figures such as Prof. Linong Ji from Peking University People’s Hospital and Prof. Stefano Genovese from Italy, who served as co-chairs. Additional speakers included Prof. Andrej Janež from Slovenia, Prof. Nina Jendrike from Germany, and Dr. Yifei Mo from China, all of whom presented cutting-edge research findings to the audience.
On the exhibition floor, SiBionics showcased its next-generation devices, the GS3 Continuous Glucose Monitoring system and the KS3 Continuous Ketone Monitoring device. These products garnered considerable attention, with attendees engaging in discussions about their technical capabilities and clinical applications. Visitors expressed keen interest in how these innovations could enhance real-world diabetes management.
A recent feasibility study confirmed that SiBionics’ CGM solution meets and exceeds the integrated CGM (iCGM) standards across multiple key performance indicators. The GS3 system demonstrated exceptional accuracy, particularly in the hypoglycemic range, surpassing iCGM requirements. This performance reinforces the device’s value in supporting clinical decision-making and improving patient self-management.
SiBionics is establishing itself as a leader in continuous monitoring technologies and is currently the only company worldwide to commercialize the CKM. The company’s robust research and development capabilities were evident at the conference, showcasing its commitment to innovation in diabetes care. As it looks to the future, SiBionics plans to expand its CKM portfolio, aiming to deliver precise, high-quality solutions that improve health outcomes for individuals living with diabetes globally.
Founded in 2015, SiBionics is headquartered in Shenzhen and Irvine. The company specializes in biosensor innovation, integrating continuous monitoring technology with smart algorithms and user-friendly software. With a workforce of over 500 employees, of which 25% are dedicated to research and development, SiBionics is dedicated to advancing personalized, data-driven health management solutions.